A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review

Xu,Chun‑Wei; Cai,Xue‑Ying; Shao,Yuan; Li,Yang; Shi,Ming‑Wei; Zhang,Li‑Ying; Wang,Lin; Zhang,Yu‑Ping; Wang,Lu‑Ping; Tian,Yu‑Wang

doi:10.3892/mmr.2015.4001

A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review

Authors:
- Chun‑Wei Xu
- Xue‑Ying Cai
- Yuan Shao
- Yang Li
- Ming‑Wei Shi
- Li‑Ying Zhang
- Lin Wang
- Yu‑Ping Zhang
- Lu‑Ping Wang
- Yu‑Wang Tian
View Affiliations

Affiliations: Department of Pathology, The General Military Hospital of Beijing PLA, Beijing 100700, P.R. China, Department of Internal Medicine, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China, Department of Surgical Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Oncology, The General Military Hospital of Beijing PLA, Beijing 100700, P.R. China
Published online on: June 26, 2015 https://doi.org/10.3892/mmr.2015.4001
Pages: 4370-4375

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The echinoderm microtubule associated protein like 4‑anaplastic lymphoma kinase (EML4‑ALK) fusion is almost mutually exclusive to epidermal growth factor receptor (EGFR) or K‑RAS mutation in non‑small cell lung cancer (NSCLC), and it is extremely rare for patients to exhibit both mutations. The present study reported the case of a 71-year‑old female diagnosed with adenocarcinoma, exhibiting mutations in EGFR and EML4‑ALK. The present study treated this patient with EGFR‑TK inhibitors, as the first line therapy, and geﬁtinib therapy revealed a good response until now. In addition, previously reported cases and associated literature were reviewed. The present study provided a greater understanding of the molecular biology and optimal treatment for patients with NSCLC with >1 driver mutation.

View Figures

View References

1	Zhou Q, Zhou CC, Chen GY, et al: A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). Lung Cancer. 83:369–373. 2014. View Article : Google Scholar : PubMed/NCBI
2	Wang Z, Zhang X, Bai H, et al: EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. Oncology. 83:248–256. 2012. View Article : Google Scholar : PubMed/NCBI
3	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
4	Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 3:13–17. 2008. View Article : Google Scholar : PubMed/NCBI
5	Koivunen JP, Mermel C, Zejnullahu K, et al: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 14:4275–4283. 2008. View Article : Google Scholar : PubMed/NCBI
6	Yang J, Zhang X, Su J, et al: Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. J Clin Oncol. 29(Suppl): [abstr 10517]. 2011.
7	Zhang X, Zhang S, Yang X, et al: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 9:1882010. View Article : Google Scholar : PubMed/NCBI
8	Kuo YW, Wu SG, Ho CC, et al: Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol. 5:2039–2040. 2010. View Article : Google Scholar : PubMed/NCBI
9	Tiseo M, Gelsomino F, Boggiani D, et al: EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer. 71:241–243. 2011. View Article : Google Scholar
10	Popat S, Vieira de Araújo A, Min T, et al: Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol. 6:1962–1963. 2011. View Article : Google Scholar : PubMed/NCBI
11	Tanaka H, Hayashi A, Morimoto T, et al: A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. BMC Cancer. 12:5582012. View Article : Google Scholar : PubMed/NCBI
12	Santelmo C, Ravaioli A, Barzotti E, et al: Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib. Lung Cancer. 81:294–296. 2013. View Article : Google Scholar : PubMed/NCBI
13	Chen X, Zhang J, Hu Q, et al: A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene. Lung Cancer. 81:308–310. 2013. View Article : Google Scholar : PubMed/NCBI
14	Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
15	Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
16	Li Y, Li Y, Yang T, et al: Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One. 8:e520932013. View Article : Google Scholar : PubMed/NCBI
17	Gazdar AF, Shigematsu H, Herz J, et al: Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers? Trends Mol Med. 10:481–486. 2004. View Article : Google Scholar : PubMed/NCBI
18	Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset. Mod Pathol. 22:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
19	Martelli MP, Sozzi G, Hernandez L, et al: EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 174:661–670. 2009. View Article : Google Scholar : PubMed/NCBI
20	Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wong DW, Leung EL, So KK, et al: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 115:1723–1733. 2009. View Article : Google Scholar : PubMed/NCBI
22	Takahashi T, Sonobe M, Kobayashi M, et al: Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 17:889–897. 2010. View Article : Google Scholar : PubMed/NCBI
23	Takeda M, Okamoto I, Sakai K, et al: Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Ann Oncol. 23:2931–2936. 2012. View Article : Google Scholar : PubMed/NCBI
24	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
25	Zornosa C, Vandergrift JL, Kalemkerian GP, et al: First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. J Natl Compr Canc Netw. 10:847–856. 2012.PubMed/NCBI
26	Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer:updated results from a phase I study. Lancet Oncol. 13:1011–1019. 2012. View Article : Google Scholar : PubMed/NCBI
27	Sasaki T, Rodig SJ, Chirieac LR and Jänne PA: The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 46:1773–1780. 2010. View Article : Google Scholar : PubMed/NCBI